Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVERTAS-2: Weight changes after switching to Dovato or Delstrigo in HIV
NCT04903847Phase 4Unknown
- Start
- Feb 2021
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir + lamivudine, doravirine in human immunodeficiency virus infection (HIV). Status: unknown.
02
Drugs
dolutegravir + lamivudinedoravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04903847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903847.